A New Comorbidity Accompanying Obesity: Renal Angiomyolipoma

Year 2021, Volume: 15 Issue: 1, 136 - 141, 09.03.2021

Aysima Bulca Acar , Remziye Nur Eke

https://doi.org/10.21763/tjfmpc.800756

Abstract

Objective: Obesity is an important health concern all around the world and considered in relation to a number of comorbidities. In this study, we aimed to evaluate the incidence of renal angiomyolipoma (AML) in obese patients. Method: This retrospective study included 288 obese patients, who were followed up at the Obesity Center of the University of Health Sciences, Antalya Training and Research Hospital between 01/11/2018 and 01/02/2020. The laboratory parameters and the reports of the abdominal ultrasound scans (USG) taken when the patients first presented to our unit were all reviewed. The patients were divided into two groups: those with and without renal AML based on the abdominal USG reports, and were compared in terms of serum hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), erythrocyte count (RBC), blood urea nitrogen (BUN), creatinine and uric acid levels. Results: Of the patients, 93.05% were female and 6.94% were male. The mean age was 51.91±9.31 (21-73) years, the average body mass index (BMI) was 36.4 (30-65.19) kg/m2. Ten patients (3.47%) had renal AML found on the abdominal USG imaging reports. While the incidence of renal AML in the general population is reported to be 0.13%-0.44%, it was found 3.47% in our study with obese patients. Conclusion:The incidence of renal AML is increasing in obese patients. Associated with many comorbidities, obesity may also constitute a risk factor for renal AML. In order to determine the relationship between obesity and AML, more studies are needed with multi-centered and broader scopes.

Keywords

Angiomyolipoma, Obesity, Prevalence

Supporting Institution

There is no support.

Thanks

We would like to thank Başak OĞUZ YOLCULAR for all the support she provided in the statistical analysis process of this study.

Obeziteye Eşlik Eden Yeni Bir Komorbidite: Renal Anjiyomiyolipom

Abstract

Amaç: Obezite bütün dünya için önemli bir sağlık sorunudur ve birçok komorbidite ile ilişkili olarak değerlendirilmektedir. Bu çalışmada; obez hastalarda renal anjiomyolipom (AML) görülme sıklığının değerlendirilmesi amaçlanmıştır. Yöntem: Retrospektif çalışmaya 01/11/2018 ile 01/02/2020 tarihleri arasında Sağlık Bilimleri Üniversitesi Antalya Hastanesi Obezite Merkezinde takipli 288 obez hasta dahil edildi. Hastaların birimimize ilk başvuruları esnasında istenmiş olan abdomen ultrasonografi (USG) raporları ile laboratuvar parametreleri tarandı. Hastalar abdomen USG raporlarında renal AML olan ve olmayan şeklinde iki gruba ayrılarak serum hemoglobin (HGB), hematokrit (HCT), ortalama eritrosit hacmi (MCV), eritrosit sayısı (RBC), kan üre azotu (BUN), kreatinin ve ürik asit düzeyleri açısından karşılaştırıldı. Bulgular: Hastaların %93,05’i kadın, %6,94’ü erkekti. Ortalama yaş 51,91±9,31 (21-73) yıl, ortalama vücut kitle indeksi (VKİ) 36,4 (30-65,19) kg/m2 idi. On hastanın (%3,47) abdomen USG raporunda renal AML vardı. Genel popülasyonda %0,13-% 0,44 olarak bildirilen renal AML insidansı, obez hastalarla yaptığımız bu çalışmada %3,47 olarak bulundu. Sonuç: Obez hastalarda renal AML görülme sıklığı artmaktadır. Birçok komorbidite ile ilişkili olan obezite durumu, renal AML için de bir risk faktörü olabilir. Obezite ile AML arasındaki ilişkiyi saptamaya yönelik çok merkezli, daha geniş kapsamlı çalışmalara ihtiyaç vardır.

Keywords

Anjiomyolipom, Obezite, Prevelans

References

• 1. Kıyan E. Obezite ve akciğer. Türkiye Klinikleri Göğüs Hastalıkları-Özel Konular 2020; 13 (1), 94-98.
• 2. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism Clinical and Experimental 2019; 92: 6-10.
• 3. Türkiye Endokrinoloji ve Metabolizma Derneği Obezite tanı ve tedavi kılavuzu 2019. Available online at http://temd.org.tr/admin/uploads/tbl_kilavuz/ 20190506163904- 2019tbl_kilavuz5ccdcb9e5d.pdf. Accessed June 8, 2020.
• 4. Dixon JB. The effect of obesity on health outcomes. Molecular and cellular endocrinology, 2010; 316 (2), 104-108.
• 5. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. Obesity, 2020; 28 (7), 1200-1204.
• 6. Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. Journal of the National Cancer Institute, 2015; 107 (2), 1-14.
• 7. Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. The Lancet Oncology, 2015; 16 (1), 36-46.
• 8. World Cancer Research Fund. Continuous Update Project Expert Report 2018. Available online at http://dietandcancerreport.org. Accessed July 8, 2020.
• 9. Vuruşkan B, Akyol S, Vuruşkan H. Renal anjiomyolipomaların klinik ve histopatolojik özellikleri: 21 olguluk seri. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2018; 44 (1), 41-44.
• 10. dos Santos MM, Proença SM, Reis MI, Viana RM, Martins LM, Colaço JM, et al. Spontaneous rupture of renal angiomyolipoma during pregnancy. Revista Brasileira de Ginecologia e Obstetrícia, 2014; 36 (8): 377-80.
• 11. Korğalı E, Ayan S. Renal anjiomiyolipomlara güncel yaklaşım. Üroonkoloji Bülteni, 2010; 9 (3), 43-46.
• 12. Vos N, Oyen R. Renal angiomyolipoma: the good, the bad, and the ugly. Journal of the Belgian Society of Radiology, 2018; 102 (1).
• 13. Lee KH, Tsai HY, Kao YT, Lin HC, Chou YC, Su SH, et al. Clinical behavior and management of three types of renal angiomyolipomas. Journal of the Formosan Medical Association, 2019; 118 (1), 162-169.
• 14. Fittschen A, Wendlik I, Oeztuerk S, Kratzer W, Akinli AS, Haenle MM, et al. Prevalence of sporadic renal angiomyolipoma: a retrospective analysis of 61,389 in-and out-patients. Abdominal imaging, 2014; 39 (5), 1009-1013.
• 15. Yılmaz E. Renal anjiomyolipom olgularının 5 yıla kadar takip görüntüleme bulguları. Kocatepe Tıp Dergisi, 2019; 20 (3), 115-120.
• 16. Adelman RD. Obesity and renal disease. Current opinion in nephrology and hypertension; 2002; 11 (3), 331-335.
• 17. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney international, 2001; 59 (4), 1498-1509.
• 18. Aurilio G, Piva F, Santoni M, Cimadamore A, Sorgentoni G, Beltran AL, et al. The role of obesity in renal cell carcinoma patients: clinical-pathological implications. International journal of molecular sciences, 2019; 20 (22), 5683.
• 19. Fujii Y, Komai Y, Saito K, Iimura Y, Yonese J, Kawakami S, et al. Incidence of benign pathologic lesions at partial nephrectomy for presumed RCC renal masses: Japanese dual-center experience with 176 consecutive patients. Urology, 2008; 72 (3), 598-602.
• 20. Oesterling, JE, Fishman, EK, Goldman SM, Marshall FF. The management of renal angiomyolipoma. The Journal of urology, 1986; 135 (6): 1121-1124.